Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Bio-Thera Solutions's FCF Margin % or its related term are showing as below:
SHSE:688177'
s FCF Margin % Range Over the Past 10 Years
Min: -96111.71 Med: -147.57 Max: 18.93
Current: -31.81
During the past 10 years, the highest FCF Margin % of Bio-Thera Solutions was 18.93%. The lowest was -96111.71%. And the median was -147.57%.
SHSE:688177's FCF Margin % is ranked better than 59.26% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs SHSE:688177: -31.81
Bio-Thera Solutions FCF Margin % Related Terms
Bio-Thera Solutions FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Thera Solutions's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688177 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Bio-Thera Solutions's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Thera Solutions FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Thera Solutions's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Thera Solutions's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Thera Solutions (SHSE:688177) has a FCF Margin % of -23.79% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio-Thera Solutions and its competitors. According to the industry distribution chart, Bio-Thera Solutions ranks #387 out of 950 companies in the Biotechnology industry, placing it in the top 40.7%.
Is Bio-Thera Solutions' FCF Margin % too high?
Bio-Thera Solutions' current FCF Margin % is -23.79%. Based on the distribution chart, Bio-Thera Solutions ranks #387 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bio-Thera Solutions has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio-Thera Solutions' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Thera Solutions ranks #387 out of 950 companies for FCF Margin %. This puts Bio-Thera Solutions in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio-Thera Solutions and its competitors. Bio-Thera Solutions's current FCF Margin % is -23.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Thera Solutions stock overvalued right now?
Based on GuruFocus' analysis, Bio-Thera Solutions (SHSE:688177) is currently considered Possible Value Trap. The stock's GF Value™ is ¥33.46, compared to a current price of ¥16.58 — trading 50.4% below its estimated fair value. The current FCF Margin % is -23.79%. Bio-Thera Solutions' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bio-Thera Solutions (SHSE:688177), the current FCF Margin % is -23.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Thera Solutions (SHSE:688177) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Thera Solutions stock appears to be undervalued.
The current stock price of ¥16.58 is trading 50.4% below its estimated GF Value™ of ¥33.46.
GuruFocus considers Bio-Thera Solutions to be Possible Value Trap.
Key valuation signals for SHSE:688177:
FCF Margin %: -23.79%
GF Value™: ¥33.46 vs. price of ¥16.58 (50.4% below fair value)
No single metric tells the full story. See the SHSE:688177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
53GF Score
Get the complete analysis for SHSE:688177
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688177 has been successfully added to your 
